Zynlonta®
loncastuximab tesirine-lpyl
for injection, for intravenous use • 10mg

Please see the Important Safety Information and accompanying full Prescribing Information.

You're invited to a presentation[a]:

ZYNLONTA®: The first and only CD19-direct ADC for 3L DLBCL

Presenter

David Samuel, PharmD
Texas Oncology
Baylor-Sammons BMT Clinic

Date

4/27/2023 at 7:30 PM Central

Location

Ruth's Chris Steak House
600 E Market St, Grand Hyatt
San Antonio, Texas 78205

RSVP

Rick Aguilar
(210) 663-3478
rick.aguilar@adctherapeutics.com

[a]This program is intended only for healthcare professionals (HCPs) in the relevant therapeutic area. Guests, including spouses, partners, and family members of attendees or speakers, may not attend or partake of any meal offered unless independently qualified to attend. This is a promotional program sponsored by ADC Therapeutics and does not qualify for Continuing Medical Education (CME) or continuing education (CE) credit. ADC Therapeutics reports certain payments and other transfers of value, including meals provided to HCPs, pursuant to applicable federal and/or state laws. If you are an HCP where your employment or state of licensure limits your ability to accept a meal, please do not accept any meal offered with this program. It is recommended that you consult your legal or ethics advisor regarding any applicable limitations.

ADC THERAPEUTICS
ZYNLONTA is a registered trademark of ADC Therapeutics SA.
US-Comm-LTX-00194 November 2022
© 2022 ADC Therapeutics SA. All rights reserved.